You are now leaving a Radius Health controlled website. Radius Health does not endorse and is not responsible for the accuracy, content, practices, procedures or standards of any non-Radius Health websites.
Innovative transdermal technology enables delivery of abaloparatide molecule – a peptide - across the skin Trial success followed by regulatory approval would provide a completely unique drug administration option for postmenopausal women with osteoporosis.
WALTHAM, Mass. , Sept. 02, 2020 (GLOBE NEWSWIRE) -- Radius Health , Inc. (Nasdaq: RDUS) today announced its participation in the following conferences in September 2020. Radius Health management will host virtual meetings with investors during the Citi 15 th Annual BioPharma Virtual
TYMLOS ® patent extended to 2031, adding approximately 3½ years to the TYMLOS-SC patent life Enrollment completed for ATOM Phase 3 study assessing the efficacy and safety of abaloparatide-SC in males with osteoporosis WALTHAM, Mass. , Aug. 25, 2020 (GLOBE NEWSWIRE) -- Radius Health , Inc. (“Radius”
TYMLOS ® U.S. net sales of $50 million, with 22% year over year growth Completion of enrollment in ATOM Phase 3 expected this week Phase 3 Trials: wearABLe and EMERALD remain on track Conference call scheduled for 8:30 a.m. ET today WALTHAM, Mass. , Aug.
WALTHAM, Mass. , Aug. 10, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced the appointment of Sean Murphy to its Board of Directors with immediate effect. Sean has several decades of experience in the industry across pharmaceuticals,
WALTHAM, Mass. , July 27, 2020 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq: RDUS) announced today that it will release its second quarter financial results on Monday, August 10, 2020 . The Company will host a conference call and live audio webcast at 8:30 a.m.
Menarini licenses global development and commercialization rights of elacestrant, an oral SERD currently in late stage Phase 3 development Elacestrant further strengthens Menarini’s global oncology portfolio, recently bolstered by the acquisition of Stemline Therapeutics in the U.S.
Radius partner Teijin Pharma has submitted a New Drug Application for abaloparatide-SC for treatment of osteoporosis in Japan WALTHAM, Mass. , May 27, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), today announced that its partner, Teijin Pharma Limited
TYMLOS® U.S. net sales of $48 million, with 61% year over year growth Our three Phase 3 studies continue to advance amid slowdown in recruitment due to COVID-19 pandemic. Anticipated data read-outs remain on track for second half of 2021 Due to anticipated impact of pandemic, 2020 TYMLOS U.S.
WALTHAM, Mass. , April 28, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq:RDUS) today announced that the Company’s Board of Directors (the “Board”) granted G. Kelly Martin , in connection with his appointment as Chief Executive Officer and President of the Company,